In recent years, the development momentum of China's biomedical industry is strong, showing the trend of increasing industrial scale and increasing R & D investment. Some data show that the market scale of China's biomedical industry has exceeded 370 billion yuan in 2019, while in 2020, with the biomedical industry pushed to the "tuyere" and entered the "fast lane", the market scale is expected to reach nearly 400 billion yuan.

In addition, with the national attention to the biomedical industry and the continuous introduction of relevant incentive policies, the industry also predicts that the market size of China's biomedical industry will maintain a growth rate of 10% - 15% in the next five years (2020-2025), and the market size will exceed 500 billion yuan by 2025. Therefore, the prospect of China's biomedical industry is very broad, which will attract more and more investors.

In fact, under the background of broad market prospect of biomedical industry, biopharmaceutical equipment is also receiving more attention in the industry. Experts said that the biopharmaceutical industry has strict requirements for the pharmaceutical environment, and the staff must be meticulous in the operation process. Under the background of the improvement of GMP standards, the health and safety of the industry need to be improved, and the production equipment must also achieve the effects of aseptic, pollution-free and green production.

It is understood that the current bio pharmaceutical equipment mainly includes bioreactors, fermentor, incubator, freeze dryer, spray dryer, centrifuge concentrator, biochemical analyzer, etc. In recent years, due to the increasingly high requirements of biopharmaceutical technology and equipment, in order to promote the better development of the biomedical industry, domestic biopharmaceutical equipment manufacturers have begun to provide batch after batch of powerful equipment, accessories and technical support for Biopharmaceutical Enterprises through continuous efforts and strengthening innovation and research.

For example, according to the "made in China 2025" plan, some bioreactor research and development enterprises actively welcome the arrival of the era of intelligent manufacturing of biopharmaceuticals, and are committed to promoting the continuous production and intelligent manufacturing of biopharmaceuticals, and innovatively developed the key equipment (bioreactor, bio engineering liquid dispensing module) and intelligent production platform (bio PAS), etc.

On the basis of years of intensive cultivation of chromatographic ultrafiltration equipment, enterprises with chromatographic ultrafiltration equipment have introduced core technology teams of precision manufacturing and automation control, strengthened their product technology innovation ability, broke through the traditional bottleneck problems, and independently developed chromatography and ultrafiltration equipment with industry leading level.

In addition, in order to meet the needs of pharmaceutical enterprises, some enterprises have further expanded their product series, launched targeted biopharmaceutical equipment and formed orders. At the same time, some enterprises rely on their accumulated high-level cold working technology, polishing technology, engineering design and installation technology to develop and produce a series of biological fermentation tanks, stainless steel tanks, laboratory reactors, electric heating reactors and other products.

At present, from the overall point of view, domestic pharmaceutical machinery and equipment have basically met the needs of the biopharmaceutical industry, but the homogenization of products has brought a lot of challenges to the market. Due to the lack of brand awareness of most pharmaceutical machinery enterprises in China, imitation and shoddy products have become the norm of the industry, which also brings great trouble to the pharmaceutical industry.

Nowadays, biomedicine has become an important industry related to the national economy and people's livelihood, and even a national strategic emerging industry. With the rapid development of domestic biopharmaceutical industry, the requirements for downstream purification process and equipment will be higher and higher in the future. Users urgently need sanitary, efficient, economic and convenient purification equipment. In this context, it is urgent for biopharmaceutical equipment enterprises to improve their independent innovation ability and develop new technologies. However, compared with the extremely mature product technology developed abroad, China is still in the development stage, which needs to accumulate a large number of talents, long-term research and experiment. Therefore, for pharmaceutical equipment enterprises, R & D and innovation still need to be slow, remember not to rush.